Skip to main content
Oxford University Hospitals NHS Foundation Trust

Alert Coronavirus / COVID-19

If you have a new continuous cough, a high temperature, or a loss or change to your sense of taste or smell, do not come to our hospitals. Follow the national advice on coronavirus (COVID-19).

Please find information on our services and visiting restrictions in our COVID-19 section.

Patients and visitors must wear a face covering in our hospitals.

This site is best viewed with a modern browser. You appear to be using an old version of Internet Explorer.

Adult solid tumours

Colorectal Carcinoma (M1)

Ovarian Carcinoma (M2)

Service under development

Endometrial Cancer

M215.2 MLH1 promoter hypermethylation

Non-Small Cell Lung Cancer (M4)

Mucoepidermoid Carcinoma (M6)

MAML2 rearrangement FISH (M6.1)

Melanoma (M7)

Uveal Melanoma (M187)

BRAF hotspot (M187.2)

Gastrointestinal Stromal Tumour (M8)

Targeted hotspot panel (KIT, PDGFRA) (M8.1)

Adenoid Cystic Carcinoma (M16)

MYB-NFIB or MYBL1-NFIB FISH (M16.1); undertaken using MYB, MYBL1 & NFIB breakapart probes

Secretory Carcinoma (Salivary Gland) (M17)

ETV6-NTRK3 FISH (M17.1); undertaken using ETV6 & NTRK3 breakapart probes

Renal Cell Carcinoma - Adult (M18)

  • TFE3 rearrangement FISH (M18.1)
  • Chromosome 3 FISH (M18.3)
  • Chromosome 8 FISH (M18.4)
  • Chromosome 7 & 17 FISH (M18.5)
  • TFEB rearrangement FISH (M18.7)
  • Additional chromosome copy number alterations can be investigated if considered clinically appropriate. These tests are not included in the TD and will be invoiced separately. Please contact us to discuss.